GL1X · GenesisL1 explorer

MolNFT v1 · #115089 · protein

Insulin regulated aminopeptidase

5C97 · Leucyl-cystinyl aminopeptidase: “Insulin regulated aminopeptidase”. X-ray diffraction, 2 ligands (NAG, ZN), 12 pockets (best druggability 0.81). MolNFT v1 #115089 on GenesisL1: 3D structure, binding sites and pockets in GL1X.

PDB
5C97
Type
protein
Length
1,711 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Leucyl-cystinyl aminopeptidase
EC
3.4.11.3
UniProt
Q9UIQ6
Ligands
NAG, ZN
Pockets
12 · best druggability 0.81

Structure

x-ray diffraction · 2 distinct chains · 43% helix, 20% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ALeucyl-cystinyl aminopeptidase (EC 3.4.11.3)protein86044% helix, 20% strandQ9UIQ6
BLeucyl-cystinyl aminopeptidase (EC 3.4.11.3)protein85142% helix, 20% strandQ9UIQ6

Ligands and binding sites

  • NAG · 2-acetamido-2-deoxy-beta-D-glucopyranose · sugar · 25 copies · chains A, B
  • ZN · Zinc ion · metal · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

12 pockets found on a 1 Å grid, 7 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
110150.810.82105empty
210840.800.81112empty
32260.610.8146empty
41650.610.8327empty
51840.600.8230empty

Interfaces

1 interface between chains.

  • A–B · 29 Ų buried · 0 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 19 glycan, 1 disulfide (N-glycosylation, disulfide).

Compared structures

  • 5C97 · Insulin regulated aminopeptidase · the same entry in another collection · chain A against A, TM-score 1.00
  • Q9UIQ6 · AlphaFold monomer V2.0 prediction for leucyl-cystinyl aminopeptidase (Q9UIQ6) · a predicted model of the same protein · chain B against A, TM-score 0.96

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.